ReviewAmerican journal of clinical and experimental urology2014
Biomarkers for bladder cancer management: present and future.
Review in American journal of clinical and experimental urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 69 citations in OpenAlex.
- Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.Journal of cancer research and clinical oncology · 2017Trial
- Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical Implementation.PloS one · 2016Trial
- Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis.ACS omega · 2025Review
- Association of Thrombomodulin Expression with Bladder Cancer Grade, Stage, and Recurrence: A Single-Center Prospective Pilot Study.Iranian journal of pathology · 2025Article
- Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Bladder cancer biomarkers: current approaches and future directions.Frontiers in oncology · 2024Review
- Unraveling the Complex Interactions between the Fat Mass and Obesity-Associated (FTO) Gene, Lifestyle, and Cancer.Advances in nutrition (Bethesda, Md.) · 2022Review
- Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test.Frontiers in genetics · 2022Article
- 5-ALA-Induced Fluorescent Cytology in the Diagnosis of Bladder Cancer-a Preliminary Report.Indian journal of surgical oncology · 2021Article
- Article
- Metabolic Evaluation of Urine from Patients Diagnosed with High Grade (HG) Bladder Cancer by SPME-LC-MS Method.Molecules (Basel, Switzerland) · 2021Article
- FTO modifies the m6A level of MALAT and promotes bladder cancer progression.Clinical and translational medicine · 2021Article
- Article
- TRIB3 Promotes the Malignant Progression of Bladder Cancer: An Integrated Analysis of Bioinformatics andFrontiers in genetics · 2021Article
- Tumor heterogeneity in muscle-invasive bladder cancer.Translational andrology and urology · 2020Review
- SLC14A1 (UT-B) gene rearrangement in urothelial carcinoma of the bladder: a case report.Diagnostic pathology · 2020Article
- Expression and correlation ofTranslational cancer research · 2020Article
- Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival.Research and reports in urology · 2020Article
- The Cells and Extracellular Matrix of Human Amniotic Membrane Hinder the Growth and Invasive Potential of Bladder Urothelial Cancer Cells.Frontiers in bioengineering and biotechnology · 2020Article
- The down-regulation of SNCG inhibits the proliferation and invasiveness of human bladder cancer cell line 5637 and suppresses the expression of MMP-2/9.International journal of clinical and experimental pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Accurate and sensitive detection of bladder cancer is critical to diagnose this deadly disease at an early stage, estimate prognosis, predict response to treatment, and monitor recurrence. In past years, laboratory diagnosis and surveillance of urinary bladder cancer have improved significantly. Although urine cytology remains the gold standard test, many new urinary biomarkers have been identified. Furthermore, recent advances in genomic studies of bladder cancer have helped to refine our understanding of the pathogenesis of the disease, the biological basis for outcome disparities, and to inform more efficient treatment and surveillance strategies. In this article, the established diagnostic tests, newly identified biomarkers and genomic landscape of bladder cancer will be reviewed.
Indexed as
Identifiers
25374904PMC4219291W1832907329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.